Second Sight Medical Products Growth, Revenue, Number of Employees and Funding

Overview

Location:
Total Funding:N/A
Industry:Medical Equip
Founded:1998
Lead Investor(s):N/A
Press

City Ranking

State Ranking

Estimated Revenue & Financials

  • Second Sight Medical Products's estimated revenue is currently $34.9M per year.
  • Second Sight Medical Products received $4.0M in venture funding in October 2018.
  • Second Sight Medical Products's estimated revenue per employee is $234154

Employee Data

  • Second Sight Medical Products has 149 Employees.
  • Second Sight Medical Products grew their employee count by -11% last year.
  • Second Sight Medical Products currently has 1 job openings.

Executive Contacts

NameTitle
David MarshSenior Director, Software Engineering
Ted RandolphVP of Manufacturing
Victoria WilinskiDirector of Materials
Mark LoarSr. Director, Regulatory Affairs
Jianing WeiDirector of Field Clinical Engineering
James MillerDirector of Manufacturing
John BlakeChief Financial Officer
Victoria AlaverdianSr. Director of Quality
Jeff WellsDirector of Business Development
Paul BrathwaiteSenior Director, Research & Development (Externals)

What Is Second Sight Medical Products?

Second Sight's mission is to restore useful vision to the blind and visually impaired. Second Sight is the leader in neuromodulation devices to treat blindness, with the most advanced technology platform delivering groundbreaking artificial vision. The recognized leader in retinitis pigmentosa, the company is committed to developing new technologies to treat the broadest population of sight-impaired individuals. Second Sight's Argus II retinal prosthesis system is an FDA and CE approved device that delivers durable, useful vision to people with severe to profound retinitis pigmentosa (RP). The Argus II has been implanted in over 300 patients worldwide, with proven durability beyond 10 years The Argus II is the standard of care for patients with severe RP, with over 25 exclusive regional centers offering the technology across North America The company is actively developing a cortical stimulation device that bypasses the diseased eye and has the potential to provide a new form of vision to individuals blinded due to a wide range of causes. If you would like to learn more about Second Sight® Medical Products or the Argus® II Retinal Prosthesis System, you can reach us at (800)350-7060.

keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals

149

Number of Employees

$34.9M

Revenue (est)

1

Current Jobs

-11%

Employee Growth %

N/A

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Caldera Medical
$23.8M10211%
JenaValve Techn...
$10.8M4644%
Anatomage
$21.1M902%
Neural Analytic...
$21.1M90-23%$73.7M
Semler Scientif...
$16.3M7027%
Bigfoot Biomedi...
$25.6M109-4%$106.9M
Enlitic
$10M4343%
Companion Medic...
$12M5146%
Intersect ENT
$94.1M40116%
Centro Medico D...
$19.8M859%

Second Sight Medical Products News

09/03/2019 - How Many Second Sight Medical Products, Inc. (NASDAQ ...

So shareholders might well want to know whether insiders have been buying or selling shares in Second Sight Medical Products, Inc.

09/09/2019 - ?Global Human Enhancement Market Top Players 2019 – 2025 ...

Vuzix, Second Sight Medical Products, Samsung Electronics, Raytheon, Magic Leap, Google, Ekso Bionics Holdings, Braingate, B-Temia.

09/03/2019 - Second Sight Medical Products, Inc. (NasdaqCM:EYES ...

Second Sight Medical Products, Inc. (NasdaqCM:EYES) boasts a Price to Book ratio of 4.937015. This ratio is calculated by dividing the current ...

Second Sight Medical Products Funding

DateAmountRoundLead InvestorsReference
2014-07-03$6.0MUndisclosedArticle
2016-06-02$19.4MUndisclosedBroadridge Corporate Issuer Solutions, IncArticle
2018-05-08$10.0MUndisclosedArticle
2018-10-23$4.0MUndisclosedArticle

Second Sight Medical Products Executive Hires

DateNameTitleReference
2016-03-25Steven D Okland JrVP Commercial U.S & CanadaArticle
2017-03-03David JacquesVice President of Research and DevelopmentArticle
2017-10-20Frank Vandeputtevp/General Manager, EMEA and Asia PacificArticle
2018-03-19Gregg WilliamsChairmanArticle
2018-03-23John BlakeCFOArticle
2018-09-05Pat RyanCOOArticle